1 week Ago By ABMN Staff
Baker Ellis Asset Management LLC trimmed its holdings in shares of Johnson & Johnson ( NYSE:JNJ – Free Report ) by 3.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,411 shares of the company’s stock after selling 296 shares during the period.
Baker Ellis Asset Management LLC’s holdings in Johnson & Johnson were worth $1,072,000 at the end of the most recent reporting period. Several other institutional investors also recently added to or reduced their stakes in JNJ. IFS Advisors LLC lifted its position in shares of Johnson & Johnson by 138.
9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new stake in Johnson & Johnson during the third quarter valued at about $31,000.
RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson during the third quarter worth about $35,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of Johnson & Johnson by 58.7% in the third quarter.
Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $40,000. Institutional investors own 69.
55% of the company’s stock. Johnson & Johnson Trading Up 0.1 % NYSE JNJ opened at $146.
76 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.
03 and a debt-to-equity ratio of 0.45. The stock’s 50-day simple moving average is $147.
85 and its two-hundred day simple moving average is $155.99. Johnson & Johnson has a twelve month low of $140.
68 and a twelve month high of $168.85. The company has a market capitalization of $353.
34 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.
51. Johnson & Johnson Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.
24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.
38%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.
59%. Wall Street Analysts Forecast Growth JNJ has been the subject of a number of recent research reports. StockNews.
com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Guggenheim boosted their price objective on Johnson & Johnson from $156.00 to $162.
00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Raymond James cut their target price on Johnson & Johnson from $170.00 to $165.
00 and set an “outperform” rating for the company in a research note on Thursday. Morgan Stanley decreased their price target on Johnson & Johnson from $175.00 to $163.
00 and set an “equal weight” rating on the stock in a research report on Thursday. Finally, Citigroup cut their price objective on shares of Johnson & Johnson from $185.00 to $175.
00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.
com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.06. View Our Latest Analysis on Johnson & Johnson Insiders Place Their Bets In related news, Director Mark A.
Weinberger acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.
00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock.
The purchase was disclosed in a filing with the SEC, which is available at this link . 0.16% of the stock is currently owned by insiders.
Johnson & Johnson Profile ( Free Report ) Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Free Report ). Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.
com's FREE daily email newsletter ..
